# BrainStorm Cell Therapeutics Inc. > BrainStorm Cell Therapeutics (OTCQB: BCLI) develops NurOwn®, an autologous MSC-NTF cell therapy for ALS, under an FDA-agreed Special Protocol Assessment. > Ticker BCLI on the OTCQB. Every URL: https://brainstorm-cell.com/sitemap.xml ## Newsroom - [Press releases](https://brainstorm-cell.com/news/press-releases/): Every press release BrainStorm Cell Therapeutics has issued since 2014, from clinical and regulatory milestones to financial results and corporate updates. - [2026 news archive](https://brainstorm-cell.com/news/2026/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2026, listed newest first with the full text of each. - [2025 news archive](https://brainstorm-cell.com/news/2025/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2025, listed newest first with the full text of each. - [2024 news archive](https://brainstorm-cell.com/news/2024/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2024, listed newest first with the full text of each. - [2023 news archive](https://brainstorm-cell.com/news/2023/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2023, listed newest first with the full text of each. - [2022 news archive](https://brainstorm-cell.com/news/2022/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2022, listed newest first with the full text of each. - [2021 news archive](https://brainstorm-cell.com/news/2021/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2021, listed newest first with the full text of each. - [2020 news archive](https://brainstorm-cell.com/news/2020/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2020, listed newest first with the full text of each. - [2019 news archive](https://brainstorm-cell.com/news/2019/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2019, listed newest first with the full text of each. - [2018 news archive](https://brainstorm-cell.com/news/2018/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2018, listed newest first with the full text of each. - [2017 news archive](https://brainstorm-cell.com/news/2017/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2017, listed newest first with the full text of each. - [2016 news archive](https://brainstorm-cell.com/news/2016/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2016, listed newest first with the full text of each. - [2015 news archive](https://brainstorm-cell.com/news/2015/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2015, listed newest first with the full text of each. - [2014 news archive](https://brainstorm-cell.com/news/2014/): BrainStorm Cell Therapeutics press releases, publications and presentations published during 2014, listed newest first with the full text of each. - [Newsroom](https://brainstorm-cell.com/news/): Press releases, peer-reviewed publications and conference presentations from BrainStorm Cell Therapeutics (OTCQB: BCLI), published on the company domain. ## Science - [ALS publications](https://brainstorm-cell.com/publications/als/): Peer-reviewed papers, errata and conference presentations reporting BrainStorm MSC-NTF cell results in amyotrophic lateral sclerosis, with citation metadata. - [Preclinical publications](https://brainstorm-cell.com/publications/preclinical/): Preclinical papers on MSC-NTF cells and their exosomes across ALS, multiple sclerosis, Huntington disease, Parkinson disease and autism spectrum models. - [Progressive MS publications](https://brainstorm-cell.com/publications/progressive-ms/): Peer-reviewed results and conference presentations from the BrainStorm MSC-NTF cell program in progressive multiple sclerosis, including the Phase 2 study. - [Peer-reviewed publications](https://brainstorm-cell.com/publications/peer-reviewed/): Peer-reviewed papers, errata and supplements reporting BrainStorm MSC-NTF cell work in ALS and progressive multiple sclerosis, with citation metadata. - [Conference presentations](https://brainstorm-cell.com/publications/presentations/): Posters and oral presentations on the BrainStorm MSC-NTF cell program given at NEALS, ECTRIMS, MDA, ENCALS and other scientific meetings since 2017. - [The science behind NurOwn®](https://brainstorm-cell.com/science/): How BrainStorm produces autologous MSC-NTF cells: the platform, the differentiation process, cell production at clinical scale, and the IP behind it. - [Autologous cellular therapy](https://brainstorm-cell.com/science/autologous-cellular-therapy/): Why a therapy made from the patient’s own cells needs no donor matching and no immunosuppression, and how BrainStorm applies it to neurodegeneration. - [MSC-NTF cells explained](https://brainstorm-cell.com/science/msc-ntf-cells/): How autologous MSC-NTF cells are made: bone-marrow MSCs differentiated to secrete high levels of neurotrophic factors, then delivered intrathecally. - [Autologous cell production](https://brainstorm-cell.com/science/cell-production/): How BrainStorm engineers, produces and purifies autologous MSC-NTF cells at clinical scale, and which GMP clean rooms supported Phase 3 production. - [The exosome platform](https://brainstorm-cell.com/science/exosomes/): BrainStorm’s allogeneic exosome platform: MSC-NTF-derived vesicles carrying LIF, VEGFA and GDF-15, the preclinical ARDS results, and the patents covering it. - [Intellectual property](https://brainstorm-cell.com/science/intellectual-property/): BrainStorm holds worldwide rights to clinical development and commercialization of the NurOwn® technology platform through an exclusive licensing agreement. - [Publications & presentations](https://brainstorm-cell.com/publications/): Every peer-reviewed paper, erratum, supplement and conference poster from the NurOwn® program, each with its own page and citation metadata. ## Pipeline - [Clinical development pipeline](https://brainstorm-cell.com/pipeline/): BrainStorm’s clinical programs: NurOwn® in ALS and progressive MS, plus preclinical MSC-NTF work in Huntington’s, Parkinson’s and autism spectrum disorder. - [NurOwn® (debamestrocel) in ALS](https://brainstorm-cell.com/pipeline/als/): NurOwn® (debamestrocel) in ALS: the Phase 3b trial design, the four completed studies, the biomarker findings, and the ALSFRS-R endpoint explained. - [MSC-NTF cells in progressive MS](https://brainstorm-cell.com/pipeline/progressive-ms/): BrainStorm’s completed Phase 2 open-label study of repeat intrathecal MSC-NTF cell administration in primary and secondary progressive multiple sclerosis. ## Patients & caregivers - [Patients & caregivers](https://brainstorm-cell.com/patients/): What ALS is, the clinical trials BrainStorm has conducted and plans to conduct, how expanded access works, and where to find advocacy and support. - [What ALS is](https://brainstorm-cell.com/patients/about-als/): Amyotrophic lateral sclerosis explained: what happens to motor neurons, how the disease progresses, and how progression is measured in clinical trials. - [ALS & progressive MS clinical trials](https://brainstorm-cell.com/patients/clinical-trials/): Which BrainStorm ALS and progressive MS studies have run, where the Phase 3 sites were, who the investigators are, and what taking part involves. - [Expanded access & compassionate use](https://brainstorm-cell.com/patients/expanded-access/): BrainStorm’s expanded access and compassionate use policy for people living with ALS, and why access is currently limited to the Phase 3b trial. - [ALS & MS support organizations](https://brainstorm-cell.com/patients/resources/): Advocacy, education and support organizations for people living with ALS or multiple sclerosis, and for the families and caregivers supporting them. ## Investors - [Investors](https://brainstorm-cell.com/investors/): BrainStorm Cell Therapeutics investor information: OTCQB: BCLI stock data, program milestones, SEC filings, presentations and press releases. ## About - [About BrainStorm Cell Therapeutics](https://brainstorm-cell.com/about/): BrainStorm Cell Therapeutics is a clinical-stage biotechnology company developing autologous cellular therapies for neurodegenerative disease. - [Leadership & board](https://brainstorm-cell.com/about/leadership/): The BrainStorm executive team, board of directors and scientific advisory board, spanning cell production, clinical development and regulatory affairs. - [Corporate governance](https://brainstorm-cell.com/about/corporate-governance/): BrainStorm’s board committees and their charters, plus the corporate governance guidelines, code of business conduct and ethics, and insider trading policy. ## Events and presentations - [Events and presentations](https://brainstorm-cell.com/investors/events-and-presentations/): Corporate presentations, conference posters and scientific talks from 2017 onward, plus webcasts of quarterly results and corporate update calls. ## SEC filings - [SEC filings](https://brainstorm-cell.com/investors/sec-filings/): Every BrainStorm SEC filing since January 2005, rebuilt nightly from EDGAR: annual and quarterly reports, current reports and Section 16 ownership filings. ## Email alerts - [Email alerts](https://brainstorm-cell.com/investors/email-alerts/): Sign up to receive BrainStorm Cell Therapeutics press releases by email, sent as soon as each release is issued. You can unsubscribe at any time. ## Careers - [Careers at BrainStorm Cell Therapeutics](https://brainstorm-cell.com/careers/): Work on a therapy manufactured one patient at a time. Open roles across cell production, clinical operations, regulatory affairs and patient advocacy. ## Contact - [Contact BrainStorm Cell Therapeutics](https://brainstorm-cell.com/contact/): Reach the right team at BrainStorm directly: patient and caregiver questions, investor relations, media requests, and business development and licensing. ## Legal - [Privacy and legal notes](https://brainstorm-cell.com/legal/): How BrainStorm Cell Therapeutics handles personal data collected through this website, which cookies it may use, and the terms on which the site is provided. ## Accessibility - [Accessibility statement](https://brainstorm-cell.com/accessibility/): BrainStorm’s accessibility commitment: the WCAG 2.2 AA target, what has been tested, the limitations we know about, and how to report a barrier to us. ## Sitemap - [Sitemap](https://brainstorm-cell.com/sitemap/): Every page on brainstorm-cell.com in one list, grouped by section: science, pipeline, publications, patients, investors, newsroom and company pages.